---
title: "Elevance Health EVP & CFO Sold Shares Worth Over $4.6M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302925791.md"
description: "Kaye Mark, an officer and EVP & CFO of Elevance Health, sold 10,584 shares of common stock on October 22, 2026, in multiple transactions at weighted average prices ranging from $434.00 to $447.19 per share. The reported sales totaled $4,658,357. Mark directly owned 19,919 shares after the transactions.Reporter NameKaye MarkRelationshipEVP & CFOTypeSellAmount$4,658,357SEC FilingForm 4DisclaimerThis is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC."
datetime: "2026-10-23T20:40:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302925791.md)
  - [en](https://longbridge.com/en/news/302925791.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302925791.md)
generator: "portal-rs"
---

# Elevance Health EVP & CFO Sold Shares Worth Over $4.6M

Kaye Mark, an officer and EVP & CFO of Elevance Health, sold 10,584 shares of common stock on October 22, 2026, in multiple transactions at weighted average prices ranging from $434.00 to $447.19 per share. The reported sales totaled $4,658,357. Mark directly owned 19,919 shares after the transactions.

Reporter Name

Kaye Mark

Relationship

EVP & CFO

Type

Sell

Amount

$4,658,357

SEC Filing

Form 4

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ELV.US](https://longbridge.com/en/quote/ELV.US.md)

## Related News & Research

- [Is Elevance Health (ELV) Still Undervalued Following Strong Earnings And Higher 2026 Guidance?](https://longbridge.com/en/news/302983253.md)
- [Elevance Health Q3 2026 net income rises 13% year over year to $1.34 billion](https://longbridge.com/en/news/302542349.md)
- [ELV: Q3 outperformance lifts 2026 guidance; long-term adjusted EPS growth target remains 12%](https://longbridge.com/en/news/302542475.md)
- [Elevance Health Reports Third Quarter 2026 Results; Raises Full-Year Guidance | ELV Stock News](https://longbridge.com/en/news/302545860.md)
- [Elevance Health, Inc. $ELV Shares Acquired by Robeco Institutional Asset Management B.V.](https://longbridge.com/en/news/302684364.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**